<DOC>
	<DOC>NCT02614196</DOC>
	<brief_summary>The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with episodic migraine.</brief_summary>
	<brief_title>Evaluation of LY2951742 in the Prevention of Episodic Migraine- the EVOLVE-2 Study</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Have a diagnosis of episodic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)3 beta guidelines (1.1 or 1.2) (ICHD3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50. Are currently enrolled in or have participated within the last 30 days or within 5 halflives (whichever is longer) in a clinical trial involving an investigational product. Current use or prior exposure to LY2951742 or another CGRP antibody. Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to LY2951742. History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilartype migraine) defined by IHS ICHD3 beta.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prevention</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>headache</keyword>
</DOC>